Operator Hello, and welcome to the Kenvue fourth-quarter and full-year 2024 earnings conference call. [Operator instructions] ...

According to the Pitch Madison Advertising Report (PMAR) released today, the country's AdEx is projected to reach Rs 1.2 lakh ...

TKO Group Holdings, Inc. (NYSE:TKO – Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday following insider buying activity. The company traded as high as $159.98 and ...

Annual maximum snow depth at Spencers Creek, 1954–2015, with a linear trend line shown Less moisture? Never fear, snowmaking is here El Niño, positive IOD and positive ... needed can also allow ski ...

As such, we are delighted with the strength of data across the primary and secondary endpoints of this Phase 2 study in moderate to severe ... While these positive results add to itolizumab ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

This is an important and solid study that examines the role of TFAM, a protein that helps maintain mtDNA, in mtDNA mutator mice. The authors have demonstrated that TFAM's counteractive role in mtDNA ...

Equillium, Inc., a clinical-stage biotechnology company, and Biocon have announced positive topline results from the phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, has exhibited positive results in both a Phase 2 proof-of-concept clinical study of patients with moderate to ...

As such, we are delighted with the strength of data across the primary and secondary endpoints of this Phase 2 study in moderate to severe ulcerative ... to the other arms of the study. While these ...